Circulating apolipoprotein A-I (ApoA-I) levels were lower in NAFLD patients (94.5 ± 16.16 vs 122.6 ± 25.2 mg/dL, P < 0.001) compared to controls (Fig. 1a), while apolipoprotein B (ApoB) levels was found to be higher in NAFLD patients (110.18 ± 15.14 vs 99.75 ± 14.41 mg/dL, P = 0.003) compared to controls (Fig. 1b). The gene discussed is APOA1; the disease is metabolic dysfunction-associated steatotic liver disease.